ProQR Therapeutics N.V. (0PQ.F)

1,8190 -0,0250 (-1,36%) Börsenschluss: 08:01AM CEST

ProQR Therapeutics N.V.

Zernikedreef 9
Leiden 2333 CK
Netherlands
31 88 166 7000
https://www.proqr.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 156

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Domenico Valerio Ph.D.	Founder & Independent Chairman of Supervisory Board	74k	N/A	1956
Mr. Daniel Anton de Boer	Founder, CEO & Member of Management Board	1,19M	N/A	1983
Mr. Rene K. Beukema	Chief Corporate Development Officer, General Counsel & Member of Management Board	915k	N/A	1964
Dr. Gerard Platenburg	Co-Founder & Chief Scientific Officer	22k	N/A	1964
Mr. Jurriaan Dekkers	Chief Financial Officer	N/A	N/A	1976
Ms. Sheila Sponselee	Chief People & Operations Officer	N/A	N/A	1984
Ms. Sarah Cue Kiely	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Sandra van der Kolk	Junior Financial Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Corporate Governance

ProQR Therapeutics N.V.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.